Description
Key facts
Detection method:Colorimetric,
Sample types:Cell Lysate,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 29 pg/mL,
Range:156.25 - 10000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)
Product details:
Human BTK ELISA kit (ab277089) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Human BTK protein in human cell extracts. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human BTK with 29 pg/mL sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
BTK, Bruton's tyrosine kinase, is critical for B-cell development. It sits at a major nexus for downstream signaling via phosphorylation cascades as well as phosphatidylinositol messaging. It is known to be responsible for oncogenic signaling that allows proliferation of B-cell leukemias. The antibodies in this kit were raised against the human full-length recombinant protein.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
BTK or Bruton's tyrosine kinase is an important enzyme in the body that functions mainly in signaling pathways within cells. It is known for its involvement in the development and activation of B cells and is expressed in cells of the hematopoietic system. The BTK protein has a molecular weight of about 76 kDa. Researchers can study BTK using tools like the BTK ELISA kit which helps measure its presence in biological samples. Furthermore there are specific anti-BTK antibodies which assist in the detection of BTK bands during analysis. BTK inhibitors like BTK C481S have been developed to regulate its activity.
Biological function summary
BTK plays an important role in the immune response by transmitting signals from the B cell receptor to the inside of the cell which promotes B cell maturation and survival. It operates as part of a larger signal transduction complex that includes other proteins and molecules. For accurate quantification of BTK expression a BTK sandwich ELISA kit may be utilized capturing and revealing the BTK protein's presence in sample preparations.
Pathways
BTK associates with both the B cell receptor signaling and the PI3K-Akt pathway. These pathways are critical for the proper functioning and proliferation of B cells. BTK interacts with proteins like PLCγ2 and BLNK in the signaling cascade highlighting its central role in transmitting extracellular signals to elicit appropriate cellular responses.
BTK is closely linked to X-linked agammaglobulinemia (XLA) a genetic condition marked by an absence of mature B cells. This highlights the connection between BTK function and immune competence. Moreover aberrant BTK activity has been implicated in some types of B cell malignancies such as chronic lymphocytic leukemia (CLL). The BTK pathway's dysregulation in these disorders may involve interactions with proteins like SYK suggesting that targeting BTK could offer therapeutic benefits in managing such conditions.
